All In Biotech

Drug Trial Radar · NCT07663318

A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)

A Phase 1, Single-center, Open-Label, Randomized, Three-Period, Six-Sequence, Single-Dose, Crossover Study in Healthy Participants Under Fasted or Fed Condition to Compare the Relative Bioavailability of Orally Administrated Octreotide Acetate Tablets (T25) and Orally Administrated Octreotide Acetate Delayed-Release Capsules (MYCAPSSA®) and to Assess the Food Effect on the Relative Bioavailability of Orally Administrated T25

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Jun 25, 2026

Primary completion

Jul 22, 2026

Study completion Jul 24, 2026

Sponsor

Lead sponsor
Triastek (Shanghai) LimitedIndustry
Sponsor type
Industry
Collaborators
Zibo Central Hospital
First posted
Jun 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial\] is to to Assess the Food Effect on the Relative Bioavailability of Orally Administrated T25 in healthy volunteers. The main questions it aims to answer are: 1. How much of relative bioavailability of Orally Administrated T25 compared to Mycapssa? 2. What effects does of food have on the pharmacokinetic profile of T25 when administerted under high fat diet? Participants will: Take T25 under both fast and food state or mycapssa in under fast state in Day1, Day4, and Day7, 13. A follow-up visit is scheduled on D14+(7), which is 7\~14 days after the last dose of investigational product via phone/message/WeChat or in face-to-face manner.

Conditions

  • Acromegaly

Interventions

  • T25-FastDrug

    Participants received a single dose ( 8 mg, 1 tablet) on days 1, 4, and 10 unde fast state

  • MycapssaDrug

    Participants received a single dose ( 20 mg, 1 granule on days 1, 4, and 10 under fast state

  • T25-FedDrug

    Participants received a single dose ( 8 mg, 1 tablet) on days 1, 4, and 10 unde fed state

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. bioavailabilityTime frame: From time 0 (administration) to 24 hours post-administration
  2. bioavailabilityTime frame: From time 0 (administration) to 24 hours post-administration.
  3. bioavailabilityTime frame: From 0 (administration) to 24hour
  4. bioavailabilityTime frame: From time 0 (administration) to 24 hours post-administration
  5. bioavailabilityTime frame: From time 0 (administration) to 24 hours post-administration.
  6. bioavailabilityTime frame: From time 0 (administration) to 24hour.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zibo Central Hospital

    Zibo, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.